Company / PP&E (Net)
CytomX Therapeutics, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.3M
FY2025
5-year range
$1.3M / $6.0M
FY2021-FY2025
Trend
-47.1%
vs FY2024
Sector context
#149 of 193
Health Care
What the data says
CytomX Therapeutics, Inc.'s pp&e (net) of $1M is lower than 77% of companies in the Health Care sector (FY2025). PP&E (Net) has declined for 6 consecutive years, from $7M in FY2019 to $1M in FY2025.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -28.4%.
Declined from $4M to $1M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -36.4%
- 5-Year CAGR
- -28.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 193This company $1.3M Sector average $777.6M
▼
-99.8% below sector average
Key checks
Key Insights
- CytomX Therapeutics, Inc.'s pp&e (net) has declined for 6 consecutive years.
- 5-year CAGR of -28.4%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 47.1% year-over-year.
- Ranks #149 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3M | -47.1% |
| FY2024 | $2.5M | -37.7% |
| FY2023 | $4.0M | -22.0% |
| FY2022 | $5.1M | -14.9% |
| FY2021 | $6.0M | -14.2% |
| FY2020 | $7.0M | -5.7% |
| FY2019 | $7.4M | +6.3% |
| FY2018 | $6.9M | +64.4% |
| FY2017 | $4.2M | -4.0% |
| FY2016 | $4.4M | +26.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026